To market and sell its technology for preclinical in vivo fluorescence imaging, Fluoptics
of Grenoble, France, a developer of image-guided surgical equipment, has opened an office in Cambridge, Mass. The company develops integrated solutions that combine a nonradioactive fluorescent tracer targeting cancer cells with its Fluobeam real-time optical imaging system. The proprietary device, due to enter clinical trials this year in Europe, is already available to the preclinical research market. More than 15 units have been sold worldwide. Once approved for the clinical market, the technology will help surgeons see what the naked eye cannot; e.g., it will illuminate cancer cells in real time for the surgeon performing the resection of cancerous tumors using natural light.